Skip to main content
Clinical Trials/NCT01820871
NCT01820871
Completed
Not Applicable

A Pilot Study of Self Management Using Application for Chronic Disease Care in Real siTuation (SMART) - DM

Inje University1 site in 1 country60 target enrollmentNovember 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 Diabetes Mellitus
Sponsor
Inje University
Enrollment
60
Locations
1
Primary Endpoint
fasting serum glucose and HbA1c
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the effectiveness of smartphone application for management of type 2 diabetes mellitus (DM).

Type 2 DM is an almost incurable chronic disease and continuous management is important for long-term prognosis. However, patient's compliance to conventional medical intervention is generally unsatisfactory and many patients feel difficult to access to the detail medical advice for type 2 DM.

Thus, the investigators developed a smartphone application for giving programed medical intervention to patients according to patients data; blood pressure, fasting blood sugar, body weight, calorie intake,exercise amount, etc.

Registry
clinicaltrials.gov
Start Date
November 2012
End Date
October 2013
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Jongha Park

Study principal investigator

Inje University

Eligibility Criteria

Inclusion Criteria

  • Type 2 DM using oral hypoglycemic agent
  • 6.5% \< HbA1c \< 10%
  • systolic blood pressure \> 130 mmHg or diastolic blood pressure \> 80 mmHg
  • BMI over 23.0
  • 20 \< age \< 70
  • smartphone user (android OS based)

Exclusion Criteria

  • Serum fasting glucose \> 250 mg/L or post prandial 2 hour serum glucose \> 350 mg/L
  • systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg
  • Diabetes mellitus patient using insulin
  • severe chronic diabetic complications (diabetic foot ulcer, severe diabetic retinopathy, diabetic nephropathy with severe proteinuria)
  • congestive heart failure (NYHA III-IV or left ventricular ejection fraction \< 30%)
  • Aspartate aminotransferase (AST) or alanine transaminase (ALT) over 3 times of upper normal limit
  • Serum creatinine \> 1.5 mg/dL
  • refusal to participate in the study
  • drug addiction or alcohol addiction
  • major psychiatric illness

Outcomes

Primary Outcomes

fasting serum glucose and HbA1c

Time Frame: 3months after enrollemnt (day 0-day 90)

we will check the fasting serum glucose and HbA1C at the day of enrollment (day0)and those at 3months after enrollment (day 90)

Secondary Outcomes

  • Lipid profile(3months after enrollment (day 0-90))
  • body weight and BMI(3months after enrollemnt (day 0-day 90))

Study Sites (1)

Loading locations...

Similar Trials